CD276 and glioblastoma: Although immune checkpoint inhibitors targeting PD-L1 and PD-1 have exhibited limited efficacy as monotherapy for glioblastoma, emerging evidence from bi-specific ADC studies incorporating B7-H3 with either PD-L1 or PD-1 has shown encouraging antitumor activity, highlighting the potential of these combination approaches in addressing therapeutic resistance [24,25].